| Title |
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, October 2016
|
| DOI | 10.1007/s00262-016-1909-3 |
| Pubmed ID | |
| Authors |
Peter Ellmark, Sara M. Mangsbo, Christina Furebring, Per Norlén, Thomas H. Tötterman |
| Abstract |
The most important goals for the field of immuno-oncology are to improve the response rate and increase the number of tumor indications that respond to immunotherapy, without increasing adverse side effects. One approach to achieve these goals is to use tumor-directed immunotherapy, i.e., to focus the immune activation to the most relevant part of the immune system. This may improve anti-tumor efficacy as well as reduce immune-related adverse events. Tumor-directed immune activation can be achieved by local injections of immune modulators in the tumor area or by directing the immune modulator to the tumor using bispecific antibodies. In this review, we focus on therapies targeting checkpoint inhibitors and co-stimulatory receptors that can generate tumor-specific T cell responses through localized immune activation. |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 54 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 19% |
| Student > Ph. D. Student | 8 | 15% |
| Student > Master | 8 | 15% |
| Professor | 4 | 7% |
| Student > Bachelor | 4 | 7% |
| Other | 9 | 17% |
| Unknown | 11 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 15 | 28% |
| Medicine and Dentistry | 9 | 17% |
| Agricultural and Biological Sciences | 6 | 11% |
| Immunology and Microbiology | 6 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Other | 2 | 4% |
| Unknown | 13 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2023.
All research outputs
#4,830,969
of 23,299,593 outputs
Outputs from Cancer Immunology, Immunotherapy
#512
of 2,920 outputs
Outputs of similar age
#79,743
of 321,229 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#10
of 35 outputs
Altmetric has tracked 23,299,593 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,920 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,229 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.